{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:55:35Z","timestamp":1789646135235,"version":"4.0.0"},"reference-count":59,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K99HL146954"],"award-info":[{"award-number":["K99HL146954"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00HL146954"],"award-info":[{"award-number":["R00HL146954"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UTHSC College of Pharmacy Research Seed Grant","award":["K99HL146954"],"award-info":[{"award-number":["K99HL146954"]}]},{"name":"UTHSC College of Pharmacy Research Seed Grant","award":["R00HL146954"],"award-info":[{"award-number":["R00HL146954"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Clinical and genetic studies strongly support a significant connection between nonalcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD) and identify ASCVD as the primary cause of death in NAFLD patients. Understanding the molecular factors and mechanisms regulating these diseases is critical for developing novel therapies that target them simultaneously. Our preliminary immunoblotting experiments demonstrated elevated expression of nidogen 2 (NID2), a basement membrane glycoprotein, in human atherosclerotic vascular tissues and murine steatotic livers. Therefore, we investigated the role of NID2 in regulating hepatosteatosis and atherosclerosis utilizing Western diet-fed Apoe\u2212\/\u2212 mice with\/without NID2 overexpression. Quantitative real-time PCR confirmed increased NID2 mRNA expression in multiple organs (liver, heart, kidney, and adipose) of NID2-overexpressing mice. Male mice with NID2 overexpression exhibited higher liver and epididymal white adipose tissue mass, increased hepatic lipid accumulation, and fibrosis. Additionally, these mice developed larger atherosclerotic lesions in the whole aortas and aortic roots, with increased necrotic core formation. Mechanistic studies showed reduced AMPK activation in the livers of NID2-overexpressing mice compared with controls, without any effects on hepatic inflammation. In conclusion, these findings suggest that NID2 plays a deleterious role in both hepatosteatosis and atherosclerosis, making it a potential therapeutic target for these conditions.<\/jats:p>","DOI":"10.3390\/ijms252312782","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:21:23Z","timestamp":1732764083000},"page":"12782","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3890","authenticated-orcid":false,"given":"Ishita","family":"Kathuria","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-645X","authenticated-orcid":false,"given":"Bal Krishan","family":"Sharma","sequence":"additional","affiliation":[{"name":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Varma","family":"Aithabathula","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvin","family":"Ofosu-Boateng","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell A.","family":"Gyamfi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-8928","authenticated-orcid":false,"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-2937","authenticated-orcid":false,"given":"Frank","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-4325","authenticated-orcid":false,"given":"Udai P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupesh","family":"Singla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: Definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"154318","DOI":"10.1016\/j.metabol.2020.154318","article-title":"Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)","volume":"111S","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Finney, A.C., Das, S., Kumar, D., McKinney, M.P., Cai, B., Yurdagul, A., and Rom, O. (2023). The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1116861"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/jmbi.1998.2004","article-title":"Nidogen-2: A new basement membrane protein with diverse binding properties","volume":"282","author":"Kohfeldt","year":"1998","journal-title":"J. Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Srisuttee, R., Arayataweegool, A., Mahattanasakul, P., Tangjaturonrasme, N., Kerekhanjanarong, V., Keelawat, S., Mutirangura, A., and Kitkumthorn, N. (2020). Evaluation of NID2 promoter methylation for screening of Oral squamous cell carcinoma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6692-z"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000481798","article-title":"Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer","volume":"83","author":"Torky","year":"2018","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"152553","DOI":"10.1016\/j.prp.2019.152553","article-title":"NID2 can serve as a potential prognosis prediction biomarker and promotes the invasion and migration of gastric cancer","volume":"215","author":"Yu","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12253-019-00609-0","article-title":"Silencing NID2 by DNA Hypermethylation Promotes Lung Cancer","volume":"26","author":"Wang","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"eadl1197","DOI":"10.1126\/sciadv.adl1197","article-title":"Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response","volume":"10","author":"Pereira","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lorentzen, L.G., Yeung, K., Eldrup, N., Eiberg, J.P., Sillesen, H.H., and Davies, M.J. (2024). Proteomic analysis of the extracellular matrix of human atherosclerotic plaques shows marked changes between plaque types. Matrix Biol. Plus, 21.","DOI":"10.1016\/j.mbplus.2024.100141"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCRESAHA.123.322590","article-title":"Proteomic Atlas of Atherosclerosis: The Contribution of Proteoglycans to Sex Differences, Plaque Phenotypes, and Outcomes","volume":"133","author":"Theofilatos","year":"2023","journal-title":"Circ. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lou, Y., Li, P.H., Liu, X.Q., Wang, T.X., Liu, Y.L., Chen, C.C., and Ma, K.L. (2024). ITGAM-mediated macrophages contribute to basement membrane damage in diabetic nephropathy and atherosclerosis. BMC Nephrol., 25.","DOI":"10.1186\/s12882-024-03505-1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/CIRCRESAHA.122.321614","article-title":"Nidogen-2 is a Novel Endogenous Ligand of LGR4 to Inhibit Vascular Calcification","volume":"131","author":"Chen","year":"2022","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1161\/CIRCULATIONAHA.120.053361","article-title":"Nidogen-2 Maintains the Contractile Phenotype of Vascular Smooth Muscle Cells and Prevents Neointima Formation via Bridging Jagged1-Notch3 Signaling","volume":"144","author":"Mao","year":"2021","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2003.09.063","article-title":"Echolucent carotid plaques predict future coronary events in patients with coronary artery disease","volume":"43","author":"Honda","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1161\/01.CIR.103.17.2171","article-title":"Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: The tromso study","volume":"103","author":"Mathiesen","year":"2001","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cvr\/cvaa244","article-title":"Role of R-spondin 2 in arterial lymphangiogenesis and atherosclerosis","volume":"117","author":"Singla","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109420","DOI":"10.1016\/j.celrep.2021.109420","article-title":"Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis","volume":"36","author":"Liu","year":"2021","journal-title":"Cell. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Flessa, C.M., Nasiri-Ansari, N., Kyrou, I., Leca, B.M., Lianou, M., Chatzigeorgiou, A., Kaltsas, G., Kassi, E., and Randeva, H.S. (2022). Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415791"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/ATVBAHA.111.237693","article-title":"Animal models of atherosclerosis","volume":"32","author":"Getz","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","article-title":"An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease","volume":"78","author":"Lee","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Holmer, M., Hagstrom, H., Chen, P., Danielsson, O., Aouadi, M., Ryden, M., and Stal, P. (2022). Associations between subcutaneous adipocyte hypertrophy and nonalcoholic fatty liver disease. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-24482-1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tem.2017.05.004","article-title":"AMPK as a Therapeutic Target for Treating Metabolic Diseases","volume":"28","author":"Day","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1113\/jphysiol.2006.108506","article-title":"Activation of AMP-activated protein kinase in the liver: A new strategy for the management of metabolic hepatic disorders","volume":"574","author":"Viollet","year":"2006","journal-title":"J. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Foretz, M., Even, P.C., and Viollet, B. (2018). AMPK Activation Reduces Hepatic Lipid Content by Increasing Fat Oxidation In Vivo. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201808.0026.v1"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Song, C., Long, X., He, J., and Huang, Y. (2023). Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1081334"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI2961","article-title":"Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2","volume":"101","author":"Horton","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2018.73155","article-title":"The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases","volume":"4","author":"Piekarska","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/excr.1998.4016","article-title":"Entactin-2: A new member of basement membrane protein with high homology to entactin\/nidogen","volume":"241","author":"Kimura","year":"1998","journal-title":"Exp. Cell. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3233\/CBM-170484","article-title":"Elevated levels of serum nidogen-2 in esophageal squamous cell carcinoma","volume":"21","author":"Chai","year":"2018","journal-title":"Cancer Biomark."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.matbio.2024.09.003","article-title":"Matrix vesicles from osteoblasts promote atherosclerotic calcification","volume":"134","author":"Wang","year":"2024","journal-title":"Matrix Biol."},{"key":"ref_39","first-page":"282","article-title":"Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis","volume":"2","author":"Basaranoglu","year":"2006","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","article-title":"Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients","volume":"54","author":"Targher","year":"2005","journal-title":"Diabetes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: Old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: Common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1194\/jlr.M071522","article-title":"Genetic and hormonal control of hepatic steatosis in female and male mice","volume":"58","author":"Norheim","year":"2017","journal-title":"J. Lipid. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1042\/BJ20150844","article-title":"The arterial microenvironment: The where and why of atherosclerosis","volume":"473","author":"Yurdagul","year":"2016","journal-title":"Biochem. J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fadaei, R., Poustchi, H., Meshkani, R., Moradi, N., Golmohammadi, T., and Merat, S. (2018). Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-29639-5"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","article-title":"The protective effects of estrogen on the cardiovascular system","volume":"340","author":"Mendelsohn","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cardiores.2006.01.001","article-title":"Unravelling the cardioprotective mechanism of action of estrogens","volume":"69","author":"Moolman","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1039\/D0FO02501A","article-title":"Berbamine induced activation of the SIRT1\/LKB1\/AMPK signaling axis attenuates the development of hepatic steatosis in high-fat diet-induced NAFLD rats","volume":"12","author":"Sharma","year":"2021","journal-title":"Food Funct."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12944-019-1136-y","article-title":"Hepatitis C virus nonstructural protein 5A perturbs lipid metabolism by modulating AMPK\/SREBP-1c signaling","volume":"18","author":"Meng","year":"2019","journal-title":"Lipids. Health Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E730","DOI":"10.1152\/ajpendo.00225.2016","article-title":"Treatment of nonalcoholic fatty liver disease: Role of AMPK","volume":"311","author":"Smith","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCRESAHA.115.304538","article-title":"AMPK-dependent inhibitory phosphorylation of ACC is not essential for maintaining myocardial fatty acid oxidation","volume":"115","author":"Zordoky","year":"2014","journal-title":"Circ. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbrc.2016.11.164","article-title":"Protective effects of gomisin N against hepatic steatosis through AMPK activation","volume":"482","author":"Yun","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: Regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kim, S., Choi, S., Dutta, M., Asubonteng, J.O., Polunas, M., Goedken, M., Gonzalez, F.J., Cui, J.Y., and Gyamfi, M.A. (2021). Pregnane X receptor exacerbates nonalcoholic fatty liver disease accompanied by obesity- and inflammation-prone gut microbiome signature. Biochem. Pharmacol., 193.","DOI":"10.1016\/j.bcp.2021.114698"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/ATVBAHA.122.318904","article-title":"CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses Lymphangiogenesis and Promotes Atherosclerosis","volume":"43","author":"Singla","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1093\/cvr\/cvab369","article-title":"Loss of myeloid cell-specific SIRPalpha, but not CD47, attenuates inflammation and suppresses atherosclerosis","volume":"118","author":"Singla","year":"2022","journal-title":"Cardiovasc. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/23\/12782\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:41:16Z","timestamp":1760114476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/23\/12782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":59,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252312782"],"URL":"https:\/\/doi.org\/10.3390\/ijms252312782","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}